High levels of tyrosine phosphorylated proto-Ret in sporadic pheochromocytomas

Cancer Research

Volumn 60, Issue 5, 2000, Pages 1365-1370

  Le Hir, Hervé ^b   Colucci D'Amato, Luca G ^c   Charlet Berguerand, Nicolas ^b   Plouin, Pierre François ^d   Bertagna, Xavier ^e   De Franciscis, Vittorio ^c   Thermes, Claude ^a,b  

^a CNRS   (France)

^b CENTRE DE GÉNÉTIQUE MOLÉCULAIRE   (France)

^c UNIVERSITY OF CHIETI   (Italy)

^d HÔPITAL BROUSSAIS   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOTYROSINE;

ARTICLE; CARCINOGENESIS; DNA TEMPLATE; GENE EXPRESSION; GERM LINE; HUMAN; HUMAN TISSUE; PATHOGENESIS; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIPPLE SYNDROME;

ADRENAL GLAND NEOPLASMS; DROSOPHILA PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR RECEPTORS; HUMANS; NERVE GROWTH FACTORS; NERVE TISSUE PROTEINS; PHEOCHROMOCYTOMA; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TYROSINE;

EID: 0005765990     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Ball, D. W. Clinical manifestations of multiple endocrine neoplasm type 2. In: B D. Nelkin (ed.), Genetic Mechanisms in Multiple Endocrine Neoplasia Type 2, pp. 2-20. Landes Company, 1996.
2. Eng, C. Seminars in medicine of the Beth Israel Hospital, Boston. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease. N. Engl. J. Med., 335: 943-951, 1996.
3. Plouin, P. F., Chatellier, G., Fofol, I., and Corvol, P. Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. Hypertension, 29: 1133-1139, 1997.
4. Smith, D. P., Eng, C., and Ponder, B. A. J. Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes and Hirschsprung disease. J. Cell Sci. 18 (Suppl.): 43-49, 1994.
5. Ponder, B. A. J., and Pierotti, M. A. Mutations in Ret in MEN 2. In: B. D. Nelkin (ed.). Genetic Mechanisms in Multiple Endocrine Neoplasia Type 2, pp. 21-35. Landes Company, 1996.
6. Takahashi, M., Buma, Y., Iwamoto, T., Inaguma, Y., Ikeda, H., and Hiai, H. Cloning and expression of the RET proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene, 3: 571-578, 1988.
7. Rosenthal, A. The GDNF protein family: gene ablation studies reveal what they really do and how. Neuron, 22: 201-203, 1999.
8. Goodfellow, P. J. Inherited cancers associated with the RET proto-oncogene. Curr. Opin. Genet. Dev., 4: 446-452, 1994.
9. Edery, P., Eng, C., Munnich, A., and Lyonnet, S. RET in human development and oncogenesis. BioEssays, 19: 389-395, 1997.
10. Asai, N., Iwashita, T., Matsuyama, M., and Takahashi, M. Mechanism of activation of the RET proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol. Cell. Biol., 15: 1613-1619, 1995.
11. Borrello, M. G., Smith, D. P., Pasini, B., Bongarzone, I., Greco, A., Lorenzo, M. J., Arighi, E., Miranda, C., Eng. C., Alberti, L., et al. RET activation by germline MEN2A and MEN2B mutations. Oncogene. 11: 2419-2427, 1995.
12. Santoro, M., Carlomagno, F., Romano, A., Bottaro, D. P., Dathan, N. A., Grieco, M., Fusco, A., Vecchio, G., Matoskova, B., Kraus, M. H., et al. Activation of RET as dominant transforming gene by germline mutations of MEN 2A and MEN 2B. Science (Washington DC), 267: 381-383, 1995.
13. Dahia, P. L., Toledo, S. P. Mulligan, L. M., Maher, E. R., Grossman, A. B., and Eng, C. Mutation analysis of glial cell line-derived neurotrophic factor (GDNF), a ligand for the RET/GDNF receptor a complex, in sporadic phaeochromocytomas. Cancer Res., 57: 310-313, 1997.
14. Woodward, E. R., Eng, C., McMahon, R., Voutilainen, R., Affara, N. A., Ponder, B. A., and Maher, E. R. Genetic predisposition to pheochromocytoma: analysis of candidate genes CDNF, RET, and VHL. Hum. Mol. Genet., 6: 1051-1056, 1997.
15. Santoro, M., Rosati, R., Grieco, M., Berlingjeri, M. T., Colucci D'Amato, G. L., de Franciscis, V., and Fusco, A. The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas. Oncogene. 5: 1595-1598, 1990.
16. Matias-Guiu, X., Colomer, A., Mato, E., Cuatrecasas, M., Komminoth, P., Prat, J., and Wolfe, H. Expression of the ret proto-oncogene in pheochromocytoma. An in situ hybridization and Northern blot study. J. Pathol., 176: 63-68, 1995.
17. Takaya, K., Yoshimasa, T., Arai, H., Tamura, N., Miyamoto, Y., Itoh, H., and Nakao, K. Expression of the RET proto-oncogene in normal human tissues, pheochromocytomas, and other tumors of neural crest origin. J. Mol. Med., 74: 617-621, 1996.
18. Rodien, P., Jeunemaitre, X., Dumon, C., Beldjord, C., and Plouin, P. F Genetic alterations of the RET proto-oncogene in familial and sporadic pheochromocytomas. Horm. Res. (Basel), 47: 263-268, 1997.
19. Colucci-D'Amato, G. L., D'Alessio, A., Filliatreau, G., Florio, T., Di Giamberardino, L., Chiappetta, G., Vecchio, G., Fusco, A., Santoro, M., and de Franciscis, V. Presence of physiologically stimulated RET in adult rat brain: induction of RET expression during nerve regeneration. Cell Growth Diff., 7: 1081-1086, 1996.
20. Ciardiello, F., Valverius, E. M., Colucci-D'Amato, G. L., Kim. N., Bassin, R. H., and Salomon, D. S. Differential growth factors expression in transformed mouse NIH-3T3 cells. J. Cell. Biochem., 42: 45-57, 1990.
21. Jiang, W. G., and Hiscox, S. Hepatocyte growth factor/scatter factor, a cytokine playing multiple and converse roles. Histol. Histopathol., 12: 537-555, 1997.
22. Porter, A. C., and Vaillancourt, R. R. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene, 17: 1343-1352, 1998.
23. Tsuzuki, T., Takahashi, M., Asai, N., Iwashita, T., Matsuyama, M., and Asai, J. Spatial and temporal expression of the ret proto-oncogene product in embryonic, infant, and adult rat tissues. Oncogene, 10: 191-198, 1995.
24. Borrello, M. G., Smith, D. P., Pasini, B., Bongarzone, I., Greco, A., Lorenzo, M. J., Arighi, E., Miranda, C., Eng, C., Alberti, L., Bocciardi, R., Mondellini, P., Scopsi, L., Romeo, G., Ponder, B. A. J., and Pierotti, M. A. RET activation by germline MEN2A and MEN2B mutations. Oncogene, II: 2419-2417, 1995.
25. Rossel, M., Pasini, A., Chappuis, S., Geneste, O., Fournier, L., Schuffenecker, I., Takahashi, M., van Grunsven, L. A., Urdiales, J. L., Rudkin, B. B., Lenoir, G. M., and Billaud M. Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations. Oncogene, 14: 265-275, 1997.
26. Califano, D., D'Alessio, A., Colucci-D'Amalo, G. L., De Vita, G., Monaco, C., Santelli, G., Di Fiore, P. P., Vecchio, G., Fusco, A., Santoro, M., and de Franciscis, V. A potential pathogenetic mechanism for multiple endocrine neoplasia type 2 syndromes involves ret-induced impairment of terminal differentiation of neuroepithelial cells. Proc. Natl. Acad. Sci. USA, 93: 7933-7937, 1996.
27. D'Alessio, A., De Vita, G., Cali, G., Nitsch, L., Fusco, A., Vecchio, G., Santelli, G., Santoro, M., and de Franciscis, V. Expression of the RET oncogene induces differentiation of SK-N-BE neuroblastoma cells. Cell Growth Differ., 6: 1387-1394, 1995.
28. Powers, J. F., Tsokas, P., and Tischler, A. S. The ret-activating ligand GDNF is differentiative and not mitogenic for normal and neoplastic human chromaffin cells in vitro. Endocr. Pathol., 9: 325-331, 1998.
29. Maxwell, G. D., Reid, K., Elefanty, A., Bartlett, P. F., and Murphy, M. Glial cell line-derived neurotrophic factor promotes the development of adrenergic neurons in mouse neural crest cultures. Proc. Natl. Acad. Sci. USA, 93: 13274-13279, 1996.
30. Michielis, F. M., Chappuis, S., Callou, B., Pasini, A., Talbot, M., Monier, R., Lenoir, G. M., Feunteun, J., and Billaud, M. Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation. Proc. Natl. Acad. Sci. USA., 94: 3330-3335, 1997.
31. Rizzo, C., Califano, D., Colucci-D'Amato, G. L., De Vita, G., D'Alessio, A., Dathan, N. A., Fusco, A., Monaco, C., Santelli, G., Vecchio, G., Santoro, M., and de Franciscis, V. Ligand stimulation of a RET chimeric receptor carrying the activating mutation responsible for the multiple endocrine neoplasia type 2B. J. Biol. Chem., 271: 29497-29501, 1996.
32. Carlomagno, F., Melillo, R. M., Visconti, R., Salvatore, G., De Vita, G., Lupoli, G., Yu, Y., Jing, S., Vecchio, G., Fusco, A., and Santoro., M. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease. Endocrinology, 139: 3613-3619, 1998.